Cargando…
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813741/ https://www.ncbi.nlm.nih.gov/pubmed/35126377 http://dx.doi.org/10.3389/fimmu.2021.821538 |
_version_ | 1784644927344345088 |
---|---|
author | Jin, Yingqi Hou, Chen Li, Yonghao Zheng, Kang Wang, Chuan |
author_facet | Jin, Yingqi Hou, Chen Li, Yonghao Zheng, Kang Wang, Chuan |
author_sort | Jin, Yingqi |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies. |
format | Online Article Text |
id | pubmed-8813741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88137412022-02-05 mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 Jin, Yingqi Hou, Chen Li, Yonghao Zheng, Kang Wang, Chuan Front Immunol Immunology Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies. Frontiers Media S.A. 2022-01-21 /pmc/articles/PMC8813741/ /pubmed/35126377 http://dx.doi.org/10.3389/fimmu.2021.821538 Text en Copyright © 2022 Jin, Hou, Li, Zheng and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jin, Yingqi Hou, Chen Li, Yonghao Zheng, Kang Wang, Chuan mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title | mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title_full | mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title_fullStr | mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title_full_unstemmed | mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title_short | mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 |
title_sort | mrna vaccine: how to meet the challenge of sars-cov-2 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813741/ https://www.ncbi.nlm.nih.gov/pubmed/35126377 http://dx.doi.org/10.3389/fimmu.2021.821538 |
work_keys_str_mv | AT jinyingqi mrnavaccinehowtomeetthechallengeofsarscov2 AT houchen mrnavaccinehowtomeetthechallengeofsarscov2 AT liyonghao mrnavaccinehowtomeetthechallengeofsarscov2 AT zhengkang mrnavaccinehowtomeetthechallengeofsarscov2 AT wangchuan mrnavaccinehowtomeetthechallengeofsarscov2 |